Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) is a humanized monoclonal antibody that specifically recognizes and binds to CD70 molecular. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells and shows inhibitory efficacy against Burkitt’s lymphoma. MW : 150 kDa.